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Abstract
Improved life expectancy and the need for robust tools to monitor renal safety of emerging new therapies have fueled the interest in renal
function in Duchenne muscular dystrophy (DMD) patients. We aimed to establish a methodology to accurately assess their renal function. Twenty
DMD patients (5–22 years) were included in this prospective study. After obtaining medical history, all patients underwent a clinical examination,
24-hour ambulatory blood pressure monitoring, ultrasound of the kidneys, direct GFR measurement (51Cr-EDTA, mGFR), complete blood and
urine analysis. Seventeen of 20 patients were treated with corticosteroids and 5/20 with angiotensin converting enzyme inhibitor (lisinopril). No
patient suffered from urinary tract infections or other renal diseases. Hypertension (systolic or diastolic blood pressure >P95) was found in 9/20
patients (8/9 patients were on steroid treatment) and a non-dipping blood pressure profile in 13/20 subjects (10/13 patients were on steroid
treatment). Urinary protein to creatinine ratio was elevated in 17/18 patients, whereas 24-hour urine protein excretion was normal in all subjects.
Median interquartile range (IQR) mGFR was 130.4 (29.1) mL/min/1.73 m2. Hyperfiltration (mGFR >150 mL/min/1.73 m2) was found in 5/20
patients. Inverse correlation between mGFR and age was observed (R2 = 0.45, p = 0.001). Serum creatinine based estimated GFR (eGFR)
equations overestimated mGFR up to 300%. eGFR based on cystatin C Filler equation was closest to the mGFR (median eGFR (IQR) of 129.5
(39.7) mL/min/1.73 m2). Our study demonstrates a high prevalence of hyperfiltration and hypertension in children and adolescents with DMD.
Because the majority of hypertensive patients were under corticosteroid treatment, the iatrogenic cause of hypertension cannot be excluded. Serum
or urine creatinine measurements are of no value to evaluate renal function in DMD patients due to the reduced skeletal muscle mass.
© 2015 Elsevier B.V. All rights reserved.
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1. Introduction
Duchenne muscular dystrophy (DMD, MIM 310200) is an
X-linked recessive muscle disorder affecting around 1 in 3500
to 6000 newborn boys [1]. An absent or reduced expression of
the dystrophin protein, caused by mutations (mainly deletions)
in the dystrophin gene, results in progressive muscle
degeneration [2]. Without treatment patients rarely survive
beyond their teens as the disease also causes cardiorespiratory
failure. In recent decades, life expectancy of patients with
DMD has increased, due to improved respiratory, cardiac and
orthopedic treatment and potentially also due to long-term
corticosteroid treatment [3–6]. Emerging therapies, targeting
dystrophin restoration, muscle growth or pathophysiological
events downstream from the dystrophin deficiency have moved
into clinical development. Among these, RNA modulating
approaches such as antisense mediated exon skipping and
nonsense codon suppression aim to restore the production of
partially functional or full length dystrophin protein [7]. A
recent phase 1-2a study of local intramuscular administration of
the antisense oligonucleotide PRO051 showed a modest
improvement in the 6-minute walk test after 12 weeks of
extended treatment, but variable proteinuria was an adverse
event in all patients [8]. However, in general, little is known
about renal function in DMD patients. A Japanese cause-of-
death analysis reported death caused by renal failure in 14% of
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286 DMD patients [9]. The same group demonstrated increased
plasma levels of cystatin C (CysC) in more than 30% of these
patients over the age of 30 [10].
Improved life expectancy and the need for robust tools to
monitor renal safety of emerging new therapies have fueled
the interest to evaluate renal function in DMD patients.
Methodologically, estimating glomerular filtration rate (GFR)
and urinary excretion of proteins and other electrolytes in this
patient population are seriously hampered by the uselessness of
creatinine, due to reduced skeletal muscle mass. Therefore, we
evaluated other accurate and validated creatinine-independent
methods for monitoring GFR and urinary excretions. In this
regard, CysC, which is independent of muscle mass and
hydration, was suggested as a valuable alternative for
calculating estimated GFR (eGFR) in these patients [11,12].
In this study we aimed to establish a methodology for
studying renal function in patients with DMD and, using this
methodology, to describe their renal function in detail.
2. Patients and methods
2.1. Patients: medical history and clinical examination
Twenty DMD patients, aged between 5 and 22 year, with
proven mutations in the dystrophin gene attending the
neuromuscular reference center at the University Hospitals
Leuven, Belgium, were enrolled in this cross-sectional
prospective study. Medical history, personal or family history of
urinary tract infections or other renal diseases, cardiac
shortening fraction, corticosteroid regimen, treatment with
angiotensin converting enzyme inhibitors (ACEi), age of
diagnosis and ambulatory status were recorded. During a
general clinical examination, length, weight and body mass
index (BMI) were determined. Twelve non-ambulatory patients
were weighed with a hoist and their height was predicted from
their ulnar length, measured with a Harpenden anthropometer
in a sitting position, based on the formula of Gauld et al. [13].
2.2. Blood and urine analyses
The blood tests included complete blood count, electrolytes,
total serum protein, creatine kinase, 1,25-dihydroxy vitamin D,
serum creatinine (Scr), urea and CysC. The enzymatic assay
of Roche was used to determine Scr. CysC was measured
using nephelometry (BN II Nephelometer). A 24-hour
urine specimen was used to measure total protein, alfa-1
microglobulin, creatinine, electrolytes and glucose.
2.3. Ambulatory blood pressure monitoring (ABPM)
An oscillometric device (Mobil-O-Graph NG) was attached
to the non-dominant arm with an appropriate cuff.
Measurements were performed every 15 minutes during
daytime and every 30 minutes during the night and lasted for 24
hours. Except for one participant, treatment with ACEi
lisinopril was temporarily stopped 7 days before ABPM. We
used the reference values of Wühl et al. [14] defining
hypertension as a blood pressure (BP) >95th percentile. We
defined a non-dipping BP profile as a nocturnal decrease <10%
of daytime BP [15].
2.4. Renal ultrasound
Ultrasound of the urinary bladder and kidneys was
performed using a Philips iU22 ultrasound system. Bipolar
diameters were measured and compared with the reference
values according to age [16] and length [17]. We defined
nephromegaly as a kidney length > mean + 2 standard
deviations for length. We also considered kidney length
according to reference values for age.
2.5. Measured GFR (mGFR)
After administering a single bolus injection of 51Cr-EDTA,
eight blood samples were taken at 15, 30, 45, 60, 120, 180, 240
and 300 minutes after injection. Data were bi-exponentially
fitted followed by correction for body surface area (BSA),
according to the formula of Du Bois and Du Bois [18].
Hyperfiltration was defined as mGFR >150 mL/min/1.73 m2.
This value is based on reference values of Pottel et al. [19]: a
median GFR of 107.3 mL/min/1.73 m2 with a standard
deviation of 21.5 mL/min/1.73 m2 leads to a 97.5th percentile
of 150 mL/min/1.73 m2.
2.6. Estimated GFR (eGFR)
Estimated GFR values were calculated using four Scr-based
equations (Schwartz [20], Flanders Metadata [19], simple
height-independent [21], Q(height) [22]), three CysC-based
equations (Larsson [23], Filler [24], Zappitelli [25]) and two
Scr/CysC-based equations (Zappitelli [25], Bouvet [26]). Only
formulas based on enzymatic Scr and/or nephelometry were
included. The different formulas are shown in Table 1.
2.7. Statistics
SPSS 20 and GraphPad Prism 6.0 (La Jolla, CA, USA) were
used for statistical analyses. The median and interquartile range
(IQR) were calculated for all the variables. Associations
between categorical variables were evaluated using the Pearson
Chi-Square test. For continuous variables, Spearman’s rank test
was used. P-values are considered significant at the 5%
significance level but should be considered as explorative,
therefore there is no correction for multiple testing. There was
no a-priori power analysis (or sample size calculation) as there
was no pre-set hypothesis for this study. Consequently,
recruitment of patients in the DMD population for this invasive
direct mGFR measurement was limited to 20 for ethical
reasons.
2.8. Ethical approval
The study was approved by the Institutional Ethical Board of
UZ Leuven. Consent forms were signed by parents of
participants ≤17 years of age or subjects ≥18 years old. Assent
forms were signed by participants 5–17 years old.
3. Results
The clinical characteristics of the patients are presented in
Table 2.The median age was 15.5 years. Sixteen of the 20
patients were treated with daily corticosteroids (deflazacort or
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prednisone), 1 patient was treated with intermittent deflazacort
(one day on/one day off) and 5/20 patients were treated with
ACEi lisinopril. No patient had a personal or family history of
urinary tract infections or other renal diseases.
3.1. ABPM
Nine of 20 subjects had an elevated BP (BP >P95) (of which
there were 8 patients treated with steroids) and 13/20 subjects a
non-dipping BP profile (of which there were 10 patients treated
with steroids) (Table 2).
3.2. Blood and urinalysis
The blood samples showed no important electrolyte
abnormalities. Protein to creatinine ratio was elevated in 17/18
patients (not determined in two patients), while all patients had
normal 24-hour urine protein excretion. Twenty four-hour
urinary sodium excretion was between 2 and 3, between 1 and
2 and below 1 mmol/kg/day for 11/19, 4/19 and 4/19 subjects
respectively (not determined in one patient). Renal tubular
reabsorption of phosphate (TmP/GFR) was normal in all
subjects. There were no subjects with glycosuria or low
molecular weight proteinuria. Hypercalciuria (>4 mg/kg/day)
was present in three patients.
3.3. Renal ultrasound
When compared to reference values for length of the
patients, 2/20 patients showed bilateral nephromegaly and 4/20
subjects had unilateral nephromegaly. When reference values
Table 1
Overview of eGFR equations.
Serum creatinine based eGFR equations
Schwartz equation [20] eGFR = kL/Scr with k = 0.413
Flanders Metadata (FM) equation [19] eGFR = kL/Scr with k = 0.0414 × ln(Age) + 0.3018
Simple height-independent equation [21] eGFR = 107.3/(Scr/Q) with Q = 0.0270 × Age + 0.2329
Q(height) equation [22] eGFR = 107.3/(Scr/Q) with Q = 3.94 − 13.4 × L + 17.6 × L2 − 9.84 × L3 + 2.04 × L4
Cystatin C based eGFR equations
Larsson equation [23] eGFR = 77.24 × CysC−1.2623 × (1.73 m2/BSA)
Filler equation [24] eGFR = 101.962 + (1.123 × log(1/CysC))
Zappitelli equation [25] eGFR = 75.94/(CysC1.17)
Serum creatinine/Cystatin C based eGFR equations
Zappitelli equation [25] eGFR = 507.76 × e0.003 × L/CysC0.635 × (Scr × 88.4)0.547
Bouvet equation [26] eGFR = 63.2 × (Scr × 88.4/96)−0.35 × (CysC/1.2)−0.56 W/450.3 × Age0.4
L, height in cm or in Q(height) equation in m; W, weight in kg, Scr, serum creatinine in mg/dL, Cys C, cystatin C in mg/L.
Table 2
Clinical and biochemical characteristics of the DMD patients.
Mutation Age Biochemical parameters Kidney length 24-hour ABPM mGFR Medication
At
diagnosis
At
evaluation
Scr
(mg/dL)
Cys C
(mg/L)
U protein
(g/g creat)
U protein
(mg/24 hr)
SD (Right;
Left)
Day
HT y/n
Night
HT y/n
Non-
dipping
y/n
mL/min/
1.73 m2
Steroids
dose, d/p*
(mg/kg/day)
ACEi
(mg/kg/
day)
Reference values Age-
dependent
[27]
0.77 <0.17 <0.15 Length
dependent
[15]
107.3 [19]
1 Deletion exon 20–34 1.6 15 0.08 0.64 0.32 0.05 (−2; −1) n n y 112.1 / 0.19
2 Duplication exon 2 8 10 0.29 0.75 0.14 0.08 (2.5; 2.2) y y y 146.7 0.90 (d) /
3 Deletion exon 45–52 2.5 14 0.26 0.72 0.19 0.11 (2; 2.5) n y y 146.5 0.30 (d) /
4 Deletion exon 46–47 3.8 13 0.17 0.63 0.18 0.05 (2; 2.1) n n n 159.2 0.50 (d) /
5 Deletion exon 46–47 4 12 0.14 / 0.23 0.06 (1.8; 1.8) n n y 140.8 0.40 (d) /
6 Deletion exon 26 1 21 0.13 / 0.39 0.10 (−1.5; 0) y n n 160.6 0.50 (d) /
7 Deletion exon 46–51 2 12 0.12 0.84 0.28 0.06 (1.9; 2.3) y y n 121.8 0.20 (p) /
8 Deletion exon 8–16 0.6 15 0.23 0.65 0.21 0.10 (1; 2.4) n y y 160.5 0.40 (d) /
9 Deletion exon 8–16 1.6 16 0.12 0.66 0.71 0.11 (0; 1.2) y n n 122.1 0.40 (d) 0.11
10 Duplication exon 2 0.7 16 0.24 0.93 0.18 0.03 (1; 1.9) n n n 124.2 0.40 (d) /
11 Deletion exon 6 3.5 17 0.13 0.72 0.28 0.10 (−0.2; 1.2) n y y 128.7 0.35 (p) 0.07
12 Deletion exon 4 6 19 0.11 0.67 0.23 0.03 (−0.2; 0) n y y 132.1 / 0.23
13 Deletion exon 46 0.4 22 0.22 0.85 0.25 0.07 (−0.5; −1.9) n n y 117.5 0.77 (d) /
14 Deletion exon 40 3 5 0.14 0.68 0.21 0.06 (2.2; 2.1) n n n 226.3 0.15 (d) /
15 Deletion exon 45 0.7 16 0.06 1.00 / / (1.3; 1.2) n n y 136.4 / 0.12
16 Deletion exon 52- 54 0.7 16 0.10 1.04 0.49 0.13 (0; 0) n n y 85.7 0.10 (d)° /
17 Deletion exon 44–50 5 18 0.12 0.75 0.28 0.05 (1.2; 1.2) n n y 116.9 0.35 (p) /
18 Duplication exon 13–19 1.5 14 0.13 0.89 0.24 0.07 (−1.6; 0) n y y 127.3 0.45 (d) /
19 Deletion exon 62 3 8 0.18 0.66 / / (2; 1.8) n n n 165.0 0.73 (d) /
20 Duplication exon 17 0.7 17 0.11 0.89 0.40 0.07 (1.5; 2) n n y 110.7 0.50 (d) /
Median (IQR) 1.8 (2.9) 15.5 (4.3) 0.13 (0.07) 0.75 (0.22) 0.25 (0.11) 0.07 (0.05) 130.4 (29.1)
Scr, serum creatinine; Cys C, cystatin C; HT, systolic and/or diastolic blood pressure >P95; non-dipping, systolic and/or diastolic non-dipping blood pressure profile; y/n, yes/no; ACEi, angiotensin-converting-
enzyme inhibitor; d/p, deflazacort/prednisone.
* 6 mg of deflazacort is equivalent to 5 mg prednisone, °one day on/one day off [28].
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for age were used, the majority of the patients had normal
(n = 17) or decreased (<2SD) kidney size (n = 2), one patient
showed unilateral increased kidney size (>2SD). No structural
renal anomalies were observed.
3.4. GFR measurements
The eGFR values obtained by different Scr and/or CysC
based formulas and mGFR by 51Cr-EDTA are shown in Table 3.
Median (IQR) mGFR measured by 51Cr-EDTA was 130.4
(29.1) mL/min/1.73 m2. One patient had a slightly decreased
mGFR of 85.7 mL/min/1.73 m2. Five patients had mGFR
>150 mL/min/1.73 m2, indicating hyperfiltration. Median
eGFR calculated using Scr was 438.2, 439.1, 177.9 and
353.8 mL/min/1.73 m2 for Schwartz, Flanders Metadata,
Simple height-independent and Q(height) equations
respectively. Median eGFR was 142.2, 129.5 and 108.9 mL/
min/1.73 m2 using the CysC-based Larsson, Filler and
Zappitelli eGFR formulas, respectively. For the Scr/CysC
combined eGFR formulas, median eGFR was 155.9 and
169.5 mL/min/1.73 m2 for Zappitelli and Bouvet, respectively.
Overall the CysC-based Filler equation gave the best
performance compared to the true mGFR, with a bias of
10.9 mL/min/1.73 m2 and eGFR values within 30% of mGFR
in 83% (15/18) of patients and within 10% in 56% (10/18)
(Figure 1). The median (IQR) creatinine clearance calculated
using 24-hour urine collection was 174.6 (61.6) mL/min/
1.73 m2. A progressive decline in mGFR with age of the DMD
patients was observed (R2 = 0.45, p = 0.001; Figure 2).
There was no correlation between cardiac shortening
fraction, wheel chair dependency, BMI or steroid use and
mGFR, the presence of hypertension or non-dipping BP profile
(data not shown).
4. Discussion
During the lasts decades, dramatically improved clinical
care resulted in prolonged life expectancy of patients with
numerous, previously lethal genetic diseases of childhood
allowing them to survive into adulthood. These exciting
advances changed the clinical history of these patients and
revealed novel disease- or therapy-related problems including
renal dysfunction [30,31]. Muscular dystrophies are among the
most common single gene disorders with DMD being the most
frequent form affecting 1 of 3500 to 6000 newborn males.
Average life expectancy in DMD patients has shifted from
adolescence in the 70s of last century to third and fourth decade
Table 3
Prediction performance of eGFR equations.
Scr based eGFR Median eGFR (IQR) Bias ± SD Within 30% Within 10%
Schwartz equation (n = 20) 438.2 (224.8) −327.7 ± 277.9 1/20 0/20
FM equation (n = 20) 439.1 (227.7) −327.9 ± 283.9 2/20 1/20
Simple equation (n = 20) 177.9 (116.7) −42.4 ± 85.5 4/20 2/20
Q(height) equation (n = 20) 353.8 (257.3) −343.6 ± 339.4 2/20 1/20
CysC based eGFR
Larsson equation (n = 18) 142.2 (65.0) −17.5 ± 38.9 15/18 6/18
Filler equation (n = 18) 129.5 (39.7) 10.9 ± 27.7 15/18 10/18
Zappitelli equation (n = 18) 108.9 (34.7) 30.9 ± 27.2 13/18 3/18
Scr/CysC based eGFR
Zappitelli equation (n = 18) 155.9 (34.6) −17.9 ± 49.9 10/18 2/18
Bouvet equation (n = 18) 169.5 (58.6) −32.9 ± 68.4 6/18 3/18
Median mGFR (IQR) (n = 20) 130.4 (29.1)
eGFR and mGFR are expressed in mL/min/1.73 m2. Bias is calculated as mGFR-eGFR.
Fig. 1. Relation between mGFR (51Cr-EDTA) and eGFR calculated by Cystatin
C-based Filler equation.
Fig. 2. mGFR (51Cr-EDTA) as a function of age in DMD patients. The black
lines represent the 10th (81 mL/min/1.73 m2), 50th (107.3 mL/min/1.73 m2)
and 90th (135 mL/min/1.73 m2) percentiles according to Piepsz [29] and
Pottel [19]. The dotted lines represent the 2.5th (65 mL/min/1.73 m2)
and 97.5th (150 mL/min/1.73 m2) percentiles. Hyperfiltration is defined as
mGFR > 150 mL/min/1.73 m2 (=97.5th percentile.).
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of life, with some patients surviving now even in their forties
[3,4,32], mainly because of improved supportive treatment of
cardiac, respiratory and orthopedic complications [5,6]. As a
reference center for DMD we were alarmed by few recent
publications suggesting that renal function might be
compromised by this disorder [8–10]. Moreover, the emergence
of new therapeutic strategies moving into clinical development
has highlighted the need for safe and robust tools to monitor
renal safety of new compounds. This stimulated us to perform
a systematic analysis of renal function in 20 genetically
identified DMD patients to describe the natural history of the
kidney function in DMD. Furthermore, this study aimed at
providing better insight in the different eGFR equations
currently used to determine renal function and their
applicability for monitoring renal function in DMD.
As it could be expected, our study convincingly
demonstrated that serum and urine creatinine measurements are
of no value in DMD patients because of the reduced muscle
mass. All equations using Scr for calculating eGFR showed a
significant overestimation up to 300% compared to mGFR by
51Cr-EDTA clearance, considered as gold standard. Twenty-four
hours creatinine clearance was on average 1.3 times higher
compared to 51Cr-EDTA clearance and the variability was twice
as high. Urinary protein excretion expressed per gram
creatinine was slightly above the reference range in the majority
of patients, while it was normal when 24-hour protein excretion
was considered. Together these results indicate that creatinine
should not be measured in DMD for estimating kidney
function.
In contrast, CysC might be a promising marker to be used for
this purpose as it is independent of muscle mass [33–35]. CysC
is a 13.3 Da non-glycosylated basic protein produced by all
nucleated cells. Because of its low molecular weight, more than
90% of CysC is filtered in the glomeruli followed by an almost
complete degradation by tubular cells [35]. High dose steroids
are known to increase CysC production, whereas low and
medium doses seem to have no influence [36]. As no clear
cut-off steroid dose has been determined in this respect, it
remained uncertain to which extent the steroid doses
administered in 17/20 of our DMD patients could affect their
CysC levels. For the whole group CysC-based eGFR obtained
by Filler equation most closely corresponded to the mGFR,
however, for the individual patients the difference between
mGFR and eGFR was substantial in many cases. Further
studies in larger cohorts are required to evaluate whether Filler
equation might be of clinical value in DMD patients.
An interesting and rather unexpected observation of our
study was the presence of glomerular hyperfiltration found in
25% of DMD patients. Moreover, 19 of 20 patients had mGFR
values above the median reference GFR of 107.3 mL/min/
1.73 m2 [19]. Glomerular hyperfiltration has been associated
with various diseases including diabetes mellitus, polycystic
kidney disease, secondary focal segmental glomerulosclerosis,
obesity, sleep apnea, cancer and blood disorders [37].
In patients with diabetes, hyperfiltration was reported to
be a significant risk factor for developing macro- or
microalbuminuria [38]. In patients with pre-hypertension,
subpopulations with hyperfiltration were supposed to be at
increased risk for subsequent kidney damage [39]. In our study,
with an exception of one patient (age 16) having mGFR of
85 mL/min/1.73 m2, no other patients with decreased mGFR
were found, however, it is tempting to speculate that
hyperfiltration might also lead to renal dysfunction in DMD
patients in their late twenties or thirties as a progressive
decline in GFR was observed in our small cohort with
increasing age.
Hyperfiltration may also occur during an episode of acute
pyelonephritis in both normal and abnormal kidney [29]. In our
study population, none of the subjects with an elevated GFR
had a urinary tract infection in the prior history or at the
moment of the scintigraphy, making this latter cause unlikely.
Harrap et al. reported that in healthy young adults (16–24
years) with elevated blood pressure, glomerular hyperfiltration
correlated with high plasma renin [40]. An activated renin
angiotensin aldosterone system (RAAS) acts as a possible
underlying pathophysiological mechanism due to efferent
arteriolar vasoconstriction. Although plasma renin activity and
aldosterone levels were not measured in this study, rather low
renal sodium excretion might indicate RAAS activation in some
of our patients. Of note ACEi therapy was discontinued prior to
inclusion in 4/5 patients.
Another observation supporting RAAS activation was the
elevated BP and the presence of a non-dipping BP profile found
in more than 50% of the patients. The prevalence of
hypertension (47%) in our patients treated with corticosteroids
was higher compared to the previously reported larger cohort of
DMD patients who were on a daily prednisone regimen for 4
years (22%) [41]. The discordance between ours and the latter
study might be due to the use of ABPM in our patients, which
is known to be a more reliable method for BP evaluation
compared to conventional ambulant measurements [42].
Consequently, corticosteroid use should be considered as a
potential risk factor for hypertension in the DMD population
and the impact of long-term chronic steroid treatment on renal
function in DMD should be further investigated. At present, a
non-dipping BP profile in adults is a proven risk factor for target
organ damage and increases cardiovascular risk in both
hypertensive and normotensive patients [15]. Although no
correlation between hypertension or non-dipping BP profile
and cardiac shortening fraction could be observed, rigorous
follow-up of BP is of particular importance in DMD patients
because of their compromised cardiac function.
It remains an intriguing question whether mutations in the
dystrophin protein as such can underlie (are responsible for)
kidney damage rather than secondary causes such as RAAS
activation or the presence of hypertension. The expression of
non-muscular isoforms of dystrophin demonstrated in the
macular densa, mesangial and endothelial cells of the kidney
supports this possibility [43,44]. Based on our observation in
this small patient cohort, further assessment of kidney function
and morphology in animal models of DMD is an exciting area
for future research and might shed more insight in the
underlying pathophysiology of renal dysfunction in DMD
patients.
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5. Conclusions
This cross-sectional prospective study convincingly
demonstrated that serum and urine creatinine measurements are
of no value for the evaluation of kidney function in DMD
patients. Direct measurement of GFR using 51Cr-EDTA should
be used instead. Serum CysC-based equations might be an
alternative to evaluate GFR but their utility should be further
studied in larger patient cohorts. The presence of hyperfiltration
or a non-dipping blood pressure profile found in more than 50%
of the patients indicates a subtle kidney damage warranting a
rigorous follow-up of kidney function in patients with DMD
surviving into adulthood.
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